Oncotelic CBO granted performance-based RSUs

Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026.

Rhea-AI Filing Summary

Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.

Insider Trade Summary

Grant/Award: 1,500 shares

Grant/Award 1 txn

Insider Saund Saran

Role CBO

Type	Security	Shares	Price	Value
Grant/Award	Restricted stock Units F1, F2	1,500	$0.00	$0.00

Holdings After Transaction: Restricted stock Units — 1,500 contracts (Direct)

Footnotes (2)

1. F1. On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.
2. F2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

Key Figures

RSUs granted: 1,500 RSUs Underlying preferred shares: 1,500 shares Common shares per preferred share: 1,000 shares +3 more

6 metrics

RSUs granted 1,500 RSUs Restricted stock units granted to CBO Saund Saran on July 10, 2026

Underlying preferred shares 1,500 shares Each RSU represents one share of Series A Convertible Preferred Stock

Common shares per preferred share 1,000 shares Each Series A Convertible Preferred Stock share is convertible into 1,000 common shares

Potential common shares on full conversion 1,500,000 shares If all 1,500 RSUs vest, settle into preferred stock, and are fully converted

Vesting performance deadline June 30, 2027 Uplisting to a national securities exchange must occur by this date unless extended by the Board

Par value of Series A Convertible Preferred Stock $0.01 Par value per share of the issuer's Series A Convertible Preferred Stock

Key Terms

Restricted stock units, Series A Convertible Preferred Stock, performance and time-based vesting, uplisting, +1 more

5 terms

Restricted stock units financial

"the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Series A Convertible Preferred Stock financial

"one share of the issuer's Series A Convertible Preferred Stock, par value $0.01"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

performance and time-based vesting financial

"granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting"

uplisting financial

"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock"

Uplisting occurs when a company's stock moves from a less regulated, smaller exchange to a more established and widely recognized one. This transition can make the stock more accessible and attractive to a broader range of investors, potentially increasing its value and trading volume. For investors, uplisting often signals growth and stability, which can influence confidence and trading decisions.

national securities exchange regulatory

"uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027"

A national securities exchange is a regulated marketplace where buyers and sellers trade stocks, bonds and other securities and where companies meet requirements to have their shares available to the public. It matters to investors because the exchange enforces rules, provides transparent prices and a steady flow of buyers and sellers—like a supervised marketplace that helps ensure fair pricing, easier buying and selling, and basic investor protections.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oncotelic Therapeutics (OTLC) report for CBO Saund Saran?

Oncotelic Therapeutics reported that CBO Saund Saran was granted 1,500 restricted stock units (RSUs) on July 10, 2026. These RSUs are a form of equity compensation that may settle in Series A Convertible Preferred Stock if vesting conditions are met.

What are the vesting conditions for Saund Saran’s 1,500 RSUs at Oncotelic (OTLC)?

The 1,500 RSUs will vest only upon achievement of an uplisting of Oncotelic’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date), plus six months of continued service after the uplisting.

Into what securities can Saund Saran’s RSUs at Oncotelic (OTLC) ultimately convert?

Each RSU can settle into one share of Series A Convertible Preferred Stock, and each such preferred share is convertible into 1,000 shares of common stock. If all 1,500 RSUs vest and convert, they would represent up to 1,500,000 common shares.

Was Saund Saran’s Form 4 transaction in OTLC stock a market buy or sell?

No market buy or sell occurred. The Form 4 reports a grant/award acquisition (code A) of 1,500 RSUs as compensation. There were no open-market purchases or sales of Oncotelic common stock disclosed in this transaction.

How many RSUs does Saund Saran hold after this Oncotelic (OTLC) grant?

After the reported transaction, Saund Saran holds 1,500 restricted stock units directly. These units are subject to the specified performance and time-based vesting conditions before they can settle into Series A Convertible Preferred Stock and ultimately common shares.

What key date is associated with the performance condition on Saund Saran’s OTLC RSUs?

The performance condition requires an uplisting to a national securities exchange on or before June 30, 2027, unless the Board approves a later date. Vesting also depends on Saund Saran’s continued service for six months following that uplisting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saund Saran

(Last) (First) (Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS CALIFORNIA 91301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock Units(1)	$0.00	07/10/2026	07/10/2026	A		1,500		(2)	(2)	Series A Preferred Stock	1,500	$0.00	1,500	D

Explanation of Responses:

1. On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

	/s/ Saran Saund	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)